Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo Nordisk submits diabetes pill for U.S. approval

Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.

Read More »

AbbVie’s Humira Remains Top-Selling Rx Drug for 2018

AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.

Read More »

FDA approves generic valsartan amid drug shortage

The FDA – looking to ease shortages triggered by several manufacturers recalling the blood pressure medicine valsartan over possible cancer risk – approved a new generic version of the drug.

Read More »

Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control

Pacira Pharmaceuticals Inc. and MyoScience Inc., a privately held medical technology company, announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira.

Read More »

Novartis and Blackstone Launch Anthos Therapeutics With $250 Million

Private investment firm Blackstone Life Sciences along with Novartis launched Anthos Therapeutics with a $250 million investment.

Read More »

Lynparza meets main goal in pancreatic cancer study

AstraZeneca Plc said the British drugmaker’s cancer drug being jointly developed with U.S.-based Merck & Co. met the primary goal in a late-stage study for a rare type of pancreatic cancer.

Read More »

Opiant’s Mid-Stage Treatment for a Severe Eating Disorder Fails to Reach Endpoints

Shares of Opiant Pharmaceuticals fell in trading after the company announced that the Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.

Read More »

More specimen sharing would yield more breakthroughs

Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.

Read More »

Alder Submits BLA to U.S. FDA for Eptinezumab

Alder BioPharmaceuticals Inc. announced the submission of a Biologics License Application (BLA) to the U.S. FDA for eptinezumab for migraine prevention targeting the calcitonin gene-related peptide (CGRP).

Read More »

Morphic and Janssen Strike Potential $750 Million Deal

Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom